How did CMMB's expenses trend impact its Q4 2024 revenue outlook?

Chemomab's (CMMB) total expenses were not available for the specific periods ending on June 30, 2024, and September 30, 2024, in the report. However, the company's latest report period is for Q4 2024, and the latest fiscal year is for 2024, ending on December 31, 2024. Given that the estimates for revenue on June 30, 2024, and September 30, 2024, were $0, it can be inferred that the company was likely focusing on managing expenses rather than generating revenue during these periods. The impact of these expense trends on the Q4 2024 revenue outlook is not explicitly detailed in the report. However, it is clear that the company's strategy was likely to control and manage costs, which might have had a negative impact on revenue potential if certain expenses were not adequately managed.